BioNexus Gene Lab Corp. (BGLC) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    BioNexus Gene Lab Corp.

    NASDAQ: BGLC · Real-Time Price · USD
    4.82
    0.52 (12.08%)
    At close: Sep 12, 2025, 9:52 AM

    BioNexus Gene Lab Income Statement

    Financials in USD. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
    Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
    Revenue
    		 9.51M 9.77M 10.93M 13.36M
    Cost of Revenue
    		 8.22M 8.44M 9.67M 11.17M
    Gross Profit
    		 1.29M 1.33M 1.26M 2.19M
    Operating Income
    		 -1.57M -2.59M -291.18K 1.06M
    Interest Income
    		 147.64K 68.67K n/a n/a
    Pretax Income
    		 -1.59M -2.61M -303.66K 1.04M
    Net Income
    		 -1.6M -2.63M -355.97K 751.57K
    Selling & General & Admin
    		 4M 3.04M 1.73M 1.2M
    Research & Development
    		 47.51K 54.98K n/a n/a
    Other Expenses
    		 -1.19M 828.39K -179.28K -66.49K
    Operating Expenses
    		 2.86M 3.92M 1.55M 1.14M
    Interest Expense
    		 21.15K 13.93K 12.48K 12.97K
    Selling & Marketing Expenses
    		 2.03M 596.86K n/a n/a
    Cost & Expenses
    		 11.08M 12.36M 11.22M 12.31M
    Income Tax Expense
    		 3.49K 21.53K 52.31K 291.28K
    Shares Outstanding (Basic)
    		 1.78M 1.72M 1.44M 1.43M
    Shares Outstanding (Diluted)
    		 1.78M 1.72M 1.44M 1.43M
    EPS (Basic)
    		 -0.9 -1.53 -0.25 0.53
    EPS (Diluted)
    		 -0.9 -1.53 -0.25 0.53
    EBITDA
    		 -1.42M -2.49M -185.76K 1.16M
    EBIT
    		 -1.57M -2.59M -291.18K 1.06M
    Depreciation & Amortization
    		 153.14K 108.42K 105.42K 108.22K

    Add to Watchlist